Answers are grounded in this paper and cite their sources.
Background: No direct comparison exists between early bracing of adolescent idiopathic scoliosis (AIS) at curve magnitudes of 15° to 24° vs. observation until the Scoliosis Research Society-recommended criteria of ≥25°. We compared curve improvement and progression between early bracing vs. standard treatment with bracing starting at ≥25°. Methods: A retrospective review was performed among patients Risser 0 to 1 with AIS curves 15° to 24° at initial visit who were followed until skeletal maturity or surgery. Patients prescribed rigid thoracolumbar sacral orthoses (TLSO) for curves 15° to 24° (early group) were compared with a control group observed until TLSO prescription at ≥25° (standard group). A subanalysis of open triradiate cartilage status (TRC) was performed. At final follow-up, patients were categorized into curve improvement ≥6°, stable (-5° to +5°), progression ≥6°, and progression to surgical magnitude (≥45°). Results: Among 414 patients (207 early, 207 standard) matched by skeletal maturity, the early group had greater curve improvement (19% vs. 1%, p < 0.001, odds ratio 16.3), greater stability (50% vs. 37%, p = 0.007), less progression ≥6° (31% vs. 62%, p < 0.001), and less progression to a surgical magnitude (6% vs. 14%, p = 0.014) than the standard group. Patients with open TRC highlighted these differences, with the early group demonstrating greater curve improvement (18% vs. 2%, p < 0.01), greater stability (42% vs. 21%, p < 0.001), less progression ≥6° (39% vs. 77%, p < 0.001), and less progression to a surgical magnitude (9% vs. 20%, p = 0.018) than the standard group, especially those with thoracic curves 20° to 24° at initial visit (13% vs. 43%, p = 0.001). The number needed to treat was 3.3. Conclusion: Early brace treatment of AIS curves 15° to 24° is superior to observation until brace initiation at 25°, with a 16-fold increased likelihood of improving curves and reducing progression to a surgical threshold by >50%. Level of Evidence: Therapeutic Level IV. See Instructions for Authors for a complete description of levels of evidence.
No takes yet. Share an insight, caveat, or question.
Zapata et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: